Post-earnings recap
Reported
Wed, Apr 29, 2026
EPS actual
$2.65
EPS est.
$2.62
EPS surprise
+1.30%
1-day move
+3.14%
AbbVie's earnings report shows a slight miss on EPS, which may raise concerns among investors. However, the stock reaction remained flat, indicating that the market may have already priced in these expectations. Management's focus on long-term growth and R&D investments suggests they are positioning the company for future success, even amidst current challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.65 | $2.69 | +1.30% |
| Revenue | N/A | $14.7B | N/A |
Overall, management conveyed a sense of cautious optimism despite missing EPS expectations. They emphasized their commitment to innovation and future growth.
Management acknowledged the challenges in meeting EPS expectations but expressed confidence in long-term growth.
They highlighted ongoing investments in research and development as a key focus area moving forward.
AbbVie Inc. is a global biopharmaceutical company focused on developing innovative therapies for complex diseases. Operating in the Health Care sector, AbbVie is known for its strong portfolio of medications, particularly in immunology, oncology, and neuroscience, making it a significant player in the biotechnology industry.
Last quarter
In Q4 2025, AbbVie reported an EPS of $2.71, surpassing estimates by 2.03%. However, the stock dropped by 3.79% the following day, indicating mixed investor sentiment.
EPS beat streak
4Q
EPS beat rate
88%
Avg EPS surprise
+0.89%
Avg 1-day reaction
+0.81%
Analysts expect AbbVie to report solid earnings this quarter, with a consensus EPS of $2.69 and revenue of $14.7 billion. Investors are keen to see if the company can maintain its growth trajectory amid competitive pressures.
Bull case
If AbbVie beats earnings expectations and provides positive guidance, it could signal strong demand for its products, leading to a potential stock rally.
Bear case
Conversely, if AbbVie misses earnings estimates or fails to provide reassuring guidance, it may raise concerns about its growth prospects, resulting in a decline in stock price.
Key metrics to watch
EPS
$2.69Earnings per share is a key indicator of profitability and helps gauge the company's financial health.
Revenue
$14.7BTotal revenue reflects the company's ability to generate sales and is crucial for assessing growth.
The print will turn on these.
Q1
Will AbbVie achieve an EPS of $2.69 or higher?
This figure is crucial as it directly impacts investor confidence and stock performance.
Q2
What are the revenue projections for AbbVie's key products?
Understanding revenue sources will help gauge the company's growth potential and market position.
—
Est. EPS
$1.52
Est. Rev
$3.6B
Impl. Move
±39.2%
Why consensus could be wrong
The Street may underestimate AbbVie's ability to maintain revenue growth due to recent product launches that have not been fully factored into earnings estimates.
Supporting evidence
AbbVie has a strong track record of beating EPS estimates, with a 75% success rate in the last eight quarters.
The options market is pricing a larger move than historical averages, indicating heightened expectations.
Recent insider selling could suggest confidence in the company's future performance despite the sales.
Key risk
If revenue from key products exceeds $14.8 billion, it could challenge the cautious consensus.
Pre-commit to what would confirm each case.
The market is closely watching AbbVie's ability to meet or exceed earnings expectations, which could significantly influence stock performance.
Bull confirmed if
Achieving an EPS of $2.69 or better would confirm strong operational performance.
Bear confirmed if
An EPS below $2.57 would raise concerns about AbbVie's growth trajectory.
What the market is pricing for the move.
Implied Move
±4.73%
Historical Avg
±3.5%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.
Options are pricing ±4.7% while ABBV has averaged ±3.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
26.0%
Smart-money positioning from the most recent 13F filings.
Institutional
77.34%
of float
Insider
0.11%
of float
Holders
5,237
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
149,488,412 sh · $40.6B
8.46%
-0.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If AbbVie beats expectations, history suggests a potential stock increase of around +1.56%, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline of approximately -2.37%, reflecting investor disappointment and concerns about future growth.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
2
0 buys·2 sells
Members
2
House only
Est. Notional
$16,002.00–$65,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
115,396,098 sh · $31.3B
6.53%
0.4%
State Street Corporation
82,596,748 sh · $22.4B
4.67%
1.7%
Vanguard Portfolio Management LLC
48,477,996 sh · $13.2B
2.74%
-2.1%
JPMORGAN CHASE & CO
47,862,796 sh · $13.0B
2.71%
-15.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
1 trade
Net selling
Recent Transactions
Traded Sep 14, 2026 · disclosed Sep 18, 2026
$15,001.00–$50,000.00
Traded May 5, 2026 · disclosed Jun 3, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.